8-K: TScan Therapeutics Appoints New Principal Accounting Officer
Officer Appointment
TScan Therapeutics, Inc. announced the appointment of Leiden Dworak as its new Principal Accounting Officer, effective August 14, 2025.
Summary
- TScan Therapeutics, Inc. appointed Leiden Dworak as Principal Accounting Officer, effective August 14, 2025.
- Mr. Dworak, aged 41, has served as Vice President, Finance since April 2022.
- He previously held the Principal Accounting Officer role for the company from July 2023 to January 2024.
- Mr. Dworak brings 17 years of experience in financial infrastructure implementation within the biotechnology and life sciences industries.
- Prior to TScan, he held leadership roles at AVROBIO, Inc., Moderna, Inc., Merrimack Pharmaceuticals, Inc., SeraCare Life Sciences Inc., and Boston Scientific Corporation.
- Jason A. Amello transitioned from the Principal Accounting Officer role but continues as Chief Financial Officer and Principal Financial Officer.
Sentiment
Score: 6
Explanation: The appointment of an experienced individual who previously held the role suggests a stable and planned transition in financial leadership, which is mildly positive for corporate governance and operational continuity.
Positives
- Appointment of an experienced professional, Leiden Dworak, with 17 years in biotech and life sciences financial infrastructure.
- Mr. Dworak has prior experience as the company's Principal Accounting Officer (July 2023 to January 2024), indicating familiarity with the company's operations.
- Continuity in the CFO role with Jason A. Amello remaining as Chief Financial Officer and Principal Financial Officer.
Industry Context
The appointment of an experienced financial officer with a background in biotechnology and life sciences, including prior roles at companies like Moderna, Inc. and AVROBIO, Inc., aligns with the specialized financial reporting and infrastructure needs of a growing biotech firm. This move reflects a common practice in the industry to ensure robust financial oversight as companies advance their clinical and manufacturing operations.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Principal Accounting Officer | Jason A. Amello | Leiden Dworak | 2025-08-14 | Appointment of new Principal Accounting Officer; Jason A. Amello continues as CFO and Principal Financial Officer. |
Stakeholder Impact
- Shareholders: Minimal direct impact; ensures continuity and expertise in financial reporting.
- Employees: No direct impact mentioned.
- Customers/Suppliers/Creditors: No direct impact mentioned.
Key Dates
| Date | Description |
|---|---|
| 2022-04-01 | Leiden Dworak began serving as Vice President, Finance of TScan Therapeutics. |
| 2023-07-01 | Leiden Dworak served as Principal Accounting Officer of TScan Therapeutics. |
| 2024-01-01 | Leiden Dworak ceased serving as Principal Accounting Officer of TScan Therapeutics. |
| 2025-08-14 | Board of Directors appointed Leiden Dworak as Principal Accounting Officer, effective this date. Jason A. Amello ceased serving as Principal Accounting Officer. |
| 2025-08-20 | Date of filing of the Form 8-K. |
Keywords
TScan Therapeutics, TCRX, Principal Accounting Officer, Leiden Dworak, Biotechnology, Life Sciences, Financial Reporting, Corporate Governance, Management Change
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.